Enterprise Value
3.362B
Cash
303.8M
Avg Qtr Burn
-17.39M
Short % of Float
13.08%
Insider Ownership
3.89%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
travoprost-iDose® TR (IMPLANT) Details Eye disease , Primary open angle glaucoma Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Epioxa™ (Epi-on) Details Eye disease , Keratoconus | Phase 3 Data readout |